Abstract
A key barrier to the development of gene therapy remains the lack of safe, efficient and easily controllable vehicles for gene delivery. The fundamental problems associated with the viral vehicles, e.g. lack of specificity and immunogenic potential, have driven the development of non-viral systems of gene delivery. In the last decade, studies on p53 gene replacement therapy have dominated the literature. Although clinical trials of p53 gene therapy have achieved limited success, it remains the only tumor suppressor gene to be evaluated formally in clinical trials for cancer treatment, with increasing focus on delivery using non-viral systems. In this article, we particularly review current investigations on p53 gene delivery using non-viral methods, including both physical and chemical approaches, with an emphasis on the latter. The existing opportunities and challenges for successful p53 cancer gene therapy are also discussed.
Keywords: p53, gene therapy, non-viral vectors, cancer, combination therapy.
Current Medicinal Chemistry
Title:Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Volume: 22 Issue: 35
Author(s): Kai Wang, Qian Huang, Fuming Qiu and Meihua Sui
Affiliation:
Keywords: p53, gene therapy, non-viral vectors, cancer, combination therapy.
Abstract: A key barrier to the development of gene therapy remains the lack of safe, efficient and easily controllable vehicles for gene delivery. The fundamental problems associated with the viral vehicles, e.g. lack of specificity and immunogenic potential, have driven the development of non-viral systems of gene delivery. In the last decade, studies on p53 gene replacement therapy have dominated the literature. Although clinical trials of p53 gene therapy have achieved limited success, it remains the only tumor suppressor gene to be evaluated formally in clinical trials for cancer treatment, with increasing focus on delivery using non-viral systems. In this article, we particularly review current investigations on p53 gene delivery using non-viral methods, including both physical and chemical approaches, with an emphasis on the latter. The existing opportunities and challenges for successful p53 cancer gene therapy are also discussed.
Export Options
About this article
Cite this article as:
Wang Kai, Huang Qian, Qiu Fuming and Sui Meihua, Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy, Current Medicinal Chemistry 2015; 22 (35) . https://dx.doi.org/10.2174/0929867322666151001121601
DOI https://dx.doi.org/10.2174/0929867322666151001121601 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
Current HIV Research Surface Binding of Toxins and Heavy Metals by Probiotics
Mini-Reviews in Medicinal Chemistry Anti-Cancer Compounds from Terrestrial and Marine Resources -In silico and Experimental Studies
Current Computer-Aided Drug Design RNA Interference-Based Gene Silencing in Mice: The Development of a Novel Therapeutical Strategy
Current Pharmaceutical Design Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Potential Clinical Applications of Multi-functional Milk Proteins and Peptides in Cancer Management
Current Medicinal Chemistry Cranberry for Urinary Tract Infection: From Bench to Bedside
Current Topics in Medicinal Chemistry Secreted Heat Shock Protein-90α: A More Effective and Safer Target for Anti-Cancer Drugs?
Current Signal Transduction Therapy Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Aloperine Induces Apoptosis by a Reactive Oxygen Species Activation Mechanism in Human Ovarian Cancer Cells
Protein & Peptide Letters Preclinical Investigation of Radiopharmaceuticals: An Accurate and Multidisciplinary Approach
Current Radiopharmaceuticals Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics Challenges in the Correct Assessment of a Case of Aggressive Thyroid Carcinoma with Synchronous Breast Cancer: A Case Report and Review of the Literature of Essential Role of Radiopharmaceuticals
Current Radiopharmaceuticals Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Therapy of Hepatocellular Carcinoma with Rhenium-188 Lipiodol
Current Radiopharmaceuticals Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Resveratrol Counteracts Hypoxia-Induced Gastric Cancer Invasion and EMT through Hedgehog Pathway Suppression
Anti-Cancer Agents in Medicinal Chemistry Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry